|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
2020
|
|
gptkbp:ATCCode
|
L01EX21
|
|
gptkbp:brand
|
gptkb:Gavreto
|
|
gptkbp:CASNumber
|
2097132-83-2
|
|
gptkbp:chemicalClass
|
pyrimidine derivative
|
|
gptkbp:developer
|
gptkb:Roche
gptkb:Blueprint_Medicines
|
|
gptkbp:hasMolecularFormula
|
C21H22FN7O3
|
|
gptkbp:hasSMILES
|
CC1=CC(=O)N(C2=NC=NC(=C21)N3CCN(CC3)C4=NC=C(C=C4)F)C(=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pralsetinib
|
|
gptkbp:KEGGID
|
gptkb:D11741
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits RET kinase activity
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL4297598
121694966
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
constipation
fatigue
hypertension
increased liver enzymes
|
|
gptkbp:target
|
gptkb:RET_proto-oncogene
|
|
gptkbp:UNII
|
6KZ7XJX9E5
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:RET_fusion-positive_cancers
medullary thyroid cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|